Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

AzurRx BioPharma to Participate in 10th Annual LifeSci Partners Corporate Access Event

ENTO

DELRAY BEACH, Fla., Jan. 05, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that the Company will participate in the 10 th Annual LifeSci Partners Corporate Access Event.

James Sapirstein, President & CEO of AzurRx BioPharma will be participating in virtual one-on-one meetings with registered investors and pharmaceutical companies. Mr. Sapirstein will be available to provide an overview of the Company’s business and clinical development programs and discuss anticipated 2021 milestones.

Event: 10 th Annual LifeSci Partners Corporate Access Event
Dates: January 6-8 & 11-14, 2021
Registration: www.lifesciadvisors.com

About AzurRx BioPharma, Inc.
AzurRx BioPharma, Inc. (NASDAQ: AZRX) is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company has a pipeline of three gut-restricted GI assets: MS1819 – a recombinant lipase biologic for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis – with two ongoing Phase 2 clinical trials; and two clinical-stage therapies using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor; FW-420, for the treatment of grade 1 Immune Checkpoint Inhibitor Associated Colitis (ICI-AC) and diarrhea in oncology patients and FW-1022, for the treatment of COVID-19 gastrointestinal infections. The Company is headquartered in Delray Beach, Florida with clinical operations in Hayward, California. Additional information on the Company can be found at www.azurrx.com .

For more information:

AzurRx BioPharma, Inc.
1615 South Congress Avenue
Suite 103
Delray Beach, Florida 33445
Phone: (646) 699-7855
info@azurrx.com

Investor Relations contact:

LifeSci Advisors, LLC.
Hans Vitzthum, Managing Director
1 International Place, Suite 1480
Boston, MA 02110
Phone: (617) 430-7578
hans@lifesciadvisors.com


Primary Logo